论文部分内容阅读
目的评价一种新型的血清肿瘤标志物CK18-3A9在肺癌辅助诊断和疗效评估中的临床应用价值。方法应用化学发光法检测100例肺部良性疾病患者和100名正常人血清中CK18-3A9的水平以及165例肺癌患者化疗前和化疗后1个周期血清中CK18-3A9的水平。结果肺癌患者血清中CK18-3A9的水平均明显高于肺部良性疾病组和正常人组(P<0.01);CK18-3A9在腺癌中的水平和敏感性明显高于其他类型的肺癌(P<0.05);CK18-3A9在Ⅲ期+Ⅳ期中的水平明显高于Ⅰ期+Ⅱ期(P<0.05)。疾病进展患者化疗1个周期后CK18-3A9的水平明显升高(P<0.01);疾病稳定和部分缓解患者化疗1个周期后CK18-3A9的水平明显下降(P<0.01)。结论新型肿瘤标志物CK18-3A9的检测对于肺癌的辅助诊断和鉴别诊断有一定的临床应用价值,CK18-3A9可作为一种肺癌化疗疗效评价参考指标,值得在临床上推广使用。
Objective To evaluate the clinical value of a novel serum tumor marker CK18-3A9 in the diagnosis and therapeutic evaluation of lung cancer. Methods The serum levels of CK18-3A9 in 100 patients with benign lung disease and 100 normal controls were measured by chemiluminescence method. Serum levels of CK18-3A9 were measured in 165 patients with lung cancer before and after chemotherapy. Results The serum levels of CK18-3A9 in patients with lung cancer were significantly higher than those in the benign lung disease group and normal group (P<0.01). The level and sensitivity of CK18-3A9 in adenocarcinoma were significantly higher than those in other types of lung cancer (P<0.01). <0.05); The level of CK18-3A9 in stage III+IV was significantly higher than that in stage I+II (P<0.05). The level of CK18-3A9 was significantly higher in patients with disease progression after one cycle of chemotherapy (P<0.01), and the level of CK18-3A9 was significantly decreased in patients with stable and partially relieved chemotherapy after one cycle (P<0.01). Conclusion The detection of novel tumor marker CK18-3A9 has certain clinical application value for the diagnosis and differential diagnosis of lung cancer. CK18-3A9 can be used as a reference index for evaluating the efficacy of chemotherapy for lung cancer. It is worthy of promotion in clinical practice.